Learn more about Peter Attia’s digital program
Preventing Atherosclerosis: 2 Fatal Flaws with the “10 Year Risk” Approach
This video clip is from episode #185 – Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way…
#185 – Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we assess risk
“If we’re still saying the same things we said 30 years ago, it could be a problem because we should have learned how to say it better, more accurately.” —Allan Sniderman
#140 – Gerald Shulman, M.D., Ph.D.: A masterclass on insulin resistance—molecular mechanisms and clinical implications
“If we can understand insulin resistance, then that’s going to be the best way to fix diabetes, heart disease,. . .fatty liver disease, and slow down cancers.” — Gerald Shulman
#129 – Tom Dayspring, M.D.: The latest insights into cardiovascular disease and lipidology
“Atherogenic lipoproteins are really the issue behind clinical atherosclerotic vascular disease. … The data has just become so overwhelming.” —Tom Dayspring
#116 – AMA with Dom D’Agostino, Ph.D., Part I of II: Ketogenic diet, exogenous ketones, and exercise
“If you restore insulin sensitivity, you’re better able to access and burn fat.” — Dom D’Agostino
Measuring cardiovascular disease risk and the importance of apoB
Millions of Americans schedule an annual physical health examination. During their visit, many can expect to get their blood drawn for…
#22 – Tom Dayspring, M.D., FACP, FNLA – Part III of V: HDL, reverse cholesterol transport, CETP inhibitors, and apolipoproteins
“Here’s something that’s going to shock you: in an average person, anywhere from 30 to 60 percent of the cholesterol in that LDL particle arrived via an HDL particle.” –Tom Dayspring
The straight dope on cholesterol – Part II
In this post we’ll address the following concept: How does cholesterol move around our body?